The study aimed to assess the effectiveness and safety of mycophenolate mofetil (MMF) in treating ocular surface inflammatory diseases through a retrospective analysis of patient records from March 2020 to March 2022.
Fourteen patients participated, primarily diagnosed with ocular mucous membrane pemphigoid and those requiring limbal allograft transplantation, with results showing significant improvement and stability in most cases treated with MMF.
The treatment proved generally safe, with only minor side effects like constipation and nausea reported, indicating that MMF could be a promising first-line systemic treatment for these eye conditions.